Four-month real-life response to Tezepelumab in patients with multi-failure to other biologics
Allergologia et Immunopathologia · 2024
DOI: 10.15586/aei.v52i6.1161 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergologia et Immunopathologia, 2024. Verfasst von Diana Betancor und 5 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain. Hauptthemen laut MEDLINE: Asthma, Antibodies, Monoclonal, Humanized, Anti-Asthmatic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
To evaluate the response to Tezepelumab in real clinical practice, we performed an analysis of the clinical, functional, and inflammatory characteristics of 13 patients with severe asthma after completing four doses of Tezepelumab was performed. When comparing clinical parameters such as asthma control test (ACT), FENO value, exacerbations in the last 4 months, blood eosinophils and FEV1%, before receiving Tezepelumab and after four doses of Tezepelumab, statistically significant differences were found in ACT levels (p=0.0072), exacerbations (p=0.018) and FEV1% (p=0.012) before and after four doses of Tezepelumab. No statistically significant differences were found in blood eosinophils or FeNO levels, however, a mean reduction of 102.5±231 cells/mm3 and 14.67±30 ppb, respectively, was observed. Patients with a high T2 profile had significantly higher baseline FeNO (p0.05). We demonstrated, in a multicenter study, the clinical improvement associated with tezepelumab treatment in severe uncontrolled asthma, independent of inflammatory biomarkers, eosinophilic profile, or previous biological failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
- CIBER Enfermedades Respiratorias, ISCIII, Madrid, Spain.
- Allergy Department, Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.
- Allergy Department, Hospital Universitario Lucus Augusti, Lugo, Spain.
- INIBIC, A Coruña, Spain; Manuterial@gmail.com.
Zitieren
APA
Betancor, D., Bautista, S., López-Rodríguez, R., Valverde-Monge, M., Fernández-Nieto, M., & Rial, M. J. (2024). Four-month real-life response to Tezepelumab in patients with multi-failure to other biologics. Allergologia et Immunopathologia. https://doi.org/10.15586/aei.v52i6.1161
Vancouver
Betancor D, Bautista S, López-Rodríguez R, Valverde-Monge M, Fernández-Nieto M, Rial MJ. Four-month real-life response to Tezepelumab in patients with multi-failure to other biologics. Allergologia et Immunopathologia. 2024. doi:10.15586/aei.v52i6.1161
BibTeX
@article{Betancor2024,
author = {Betancor, Diana and Bautista, Sara and López-Rodríguez, Raquel and Valverde-Monge, Marcela and Fernández-Nieto, Mar and Rial, Manuel J},
title = {Four-month real-life response to Tezepelumab in patients with multi-failure to other biologics},
journal = {Allergologia et Immunopathologia},
year = {2024},
doi = {10.15586/aei.v52i6.1161}
}
EUVIMED